Published in Br J Cancer on June 01, 1984
Clinical aspects of Hodgkin's disease. BMJ (1988) 0.75
Early stage Hodgkin's disease in adults: which is the correct treatment? Postgrad Med J (1989) 0.75
Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. Br J Cancer (1987) 0.75
Radiation therapy alone versus radiation therapy and chemotherapy in the management of Hodgkin's disease. J Natl Med Assoc (1990) 0.75
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03
The radical radiotherapy of regionally localized Hodgkin's disease. Radiology (1962) 1.58
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
The management of Hodgkin's disease. Cancer (1975) 1.25
Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer (1976) 1.24
The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy. Cancer (1975) 1.10
The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood (1982) 1.06
The results of radiotherapy for Hodgkins' disease. Br J Cancer (1975) 1.06
The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer (1978) 1.05
Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer (1980) 1.04
The staging and treatment of Hodgkin's disease. N Engl J Med (1978) 1.03
Radiotherapy in the treatment of Hodgkin's disease. Br Med J (1978) 1.01
Extralymphatic Hodgkin's disease. Prognosis and response to therapy. Am J Med (1981) 0.93
Impact of salvage treatment on initial relapses in patients with Hodgkin disease, stages I-III. Blood (1978) 0.88
Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. Cancer Treat Rep (1982) 0.83
Chemotherapy--radiotherapy association in Hodgkin's disease, clinical stages IA, II2A: results of a prospective clinical trial with 166 patients. Cancer (1980) 0.82
Hodgkin's disease: combination chemotherapy for relapse following radical radiotherapy. Int J Radiat Oncol Biol Phys (1979) 0.82
[Possibilities of treatment of reduction in Hodgkin's disease. III. Can polychemotherapy when combined with radiotherapy of localised stages be reduced? (author's transl)]. Dtsch Med Wochenschr (1981) 0.78
The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal masses. Int J Radiat Oncol Biol Phys (1981) 0.78
Combined modality treatment of Hodgkin's disease confined to lymph nodes. Results eight years later. Am J Med (1979) 0.78
Embryonic stem cell lines derived from human blastocysts. Science (1998) 65.53
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet (1997) 5.97
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet (1998) 5.65
Morphological and antigenic relationships between viruses (rotaviruses) from acute gastroenteritis of children, calves, piglets, mice, and foals. Infect Immun (1976) 4.55
HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet (2004) 4.40
Curcumin: the story so far. Eur J Cancer (2005) 4.17
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer (1971) 3.57
Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth (2000) 3.46
Sequence analysis of termini of conjugative transposon Tn916. J Bacteriol (1988) 3.22
Genetic organization of the bacterial conjugative transposon Tn916. J Bacteriol (1988) 3.18
Mutation of a new sodium channel gene, Scn8a, in the mouse mutant 'motor endplate disease'. Nat Genet (1995) 2.99
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis (1983) 2.83
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
Structure and function of heparan sulphate proteoglycans. Biochem J (1986) 2.78
Reversible thyroid dysfunction during treatment with GM-CSF. Lancet (1991) 2.77
Long term follow up of women after hysterectomy with a history of pre-invasive cancer of the cervix. Br J Obstet Gynaecol (1992) 2.72
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res (2001) 2.69
Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol (1985) 2.53
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am (2006) 2.42
HPV 16 DNA in normal and malignant cervical epithelium: implications for the aetiology and behaviour of cervical neoplasia. Lancet (1987) 2.38
Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer (2000) 2.34
Angelman syndrome: consensus for diagnostic criteria. Angelman Syndrome Foundation. Am J Med Genet (1995) 2.34
Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother (1973) 2.33
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer (1999) 2.22
Anxiety caused by abnormal result of cervical smear test: a controlled trial. BMJ (1990) 2.22
Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer (2005) 2.20
Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer (1997) 2.18
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Classification of macroalgae as fuel and its thermochemical behaviour. Bioresour Technol (2008) 2.15
Prospective study of follow up alone in stage I teratoma of the testis. Br Med J (Clin Res Ed) (1983) 2.13
Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse. Cell (1997) 2.13
Demonstration and solubilization of antigens expressed primarily on the surfaces of Candida albicans germ tubes. Infect Immun (1984) 2.13
The isolation of reovirus-like agents (rota-viruses) from acute gastroenteritis of piglets. J Med Microbiol (1976) 2.12
Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry (1998) 2.11
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
Diagnosing bacterial respiratory infection by bronchoalveolar lavage. J Infect Dis (1987) 2.07
PEX19 binds multiple peroxisomal membrane proteins, is predominantly cytoplasmic, and is required for peroxisome membrane synthesis. J Cell Biol (2000) 2.07
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer (1984) 2.05
Gemcitabine--a major advance? Ann Oncol (1998) 2.05
Prevalence of disease among vinyl chloride and polyvinyl chloride workers. Ann N Y Acad Sci (1975) 2.04
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer (2004) 1.97
Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum Mol Genet (2003) 1.92
Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med (1998) 1.87
Blue babies and nitrate-contaminated well water. Environ Health Perspect (2000) 1.82
Nationwide cerebrovascular disease morbidity study. Stroke (1972) 1.82
Uniparental disomy explains the occurrence of the Angelman or Prader-Willi syndrome in patients with an additional small inv dup(15) chromosome. J Med Genet (1993) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Thio reduction of human 2 -macroglobulin. The subunit structure. Biochem J (1972) 1.79
Mitochondrial DNA polymorphism in Candida albicans. J Infect Dis (1987) 1.79
Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. BMJ (1999) 1.77
Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood (2001) 1.75
The outcome of pregnancy after cone biopsy of the cervix: a case-control study. Br J Obstet Gynaecol (1979) 1.75
Young age as a prognostic factor in cervical cancer: analysis of population based data from 10,022 cases. Br Med J (Clin Res Ed) (1988) 1.73
Enhancing effect of bacterial endotoxins on bone marrow cells in the immune response to SRBC. J Immunol (1972) 1.69
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol (1987) 1.67
Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol (1992) 1.65
Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. Dis Colon Rectum (1994) 1.64
Clinical factors associated with the non-utilization of an anaesthesia incident reporting system. Br J Anaesth (2011) 1.61
Definition of local recurrence after surgery for rectal carcinoma. Br J Surg (1995) 1.59
Analysis of cell wall extracts of Candida albicans by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot techniques. Infect Immun (1986) 1.58
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57
Appropriateness of acute medical admissions and length of stay. J R Coll Physicians Lond (1998) 1.55
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet (2001) 1.52
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Increased cancer risk in offspring of women with colorectal carcinoma: a Swedish register-based cohort study. Cancer (2000) 1.52
Evidence for two pathways of meiotic intrachromosomal recombination in yeast. Proc Natl Acad Sci U S A (1989) 1.52
Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients. Oral Oncol (2002) 1.51
Phase I clinical trial of mitozolomide. Cancer Treat Rep (1985) 1.48
Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect Immun (1980) 1.48
Venereal transmission of shigellosis in Seattle-King county. Sex Transm Dis (1978) 1.47
Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology (2005) 1.47
PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology (2003) 1.46
Isolation, purification, and radiolabeling of a novel 120-kD surface protein on Blastomyces dermatitidis yeasts to detect antibody in infected patients. J Clin Invest (1990) 1.46
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 1.45
C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med (1993) 1.45
A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol (1986) 1.43
The significance of ulcer disease on late mortality after partial gastric resection. Eur J Gastroenterol Hepatol (1997) 1.43
Identification of two germ-tube-specific cell wall antigens of Candida albicans. Infect Immun (1986) 1.43
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Prognosis of isolated seizures in adult life. Br Med J (Clin Res Ed) (1981) 1.43
Human papillomavirus type-16 homologous DNA in normal human ectocervix. Lancet (1986) 1.42
Kinetics of the antibody response to type III pneumococcal polysaccharide. I. Evidence that suppressor cells function by inhibiting the recruitment and proliferation of antibody-producing cells. J Immunol (1976) 1.42
Latest trends in cancer incidence among UK South Asians in Leicester. Br J Cancer (2003) 1.42
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41